Drug intelligence / Profile preview

EMP-014

Development stage: Preclinical
Lead developer: Empirico
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

EMP-014 is an investigational small interfering RNA (siRNA) therapeutic developed by Empirico. It is designed for the treatment of neurodegenerative diseases, with a focus on extrahepatic delivery of siRNA. The drug leverages human genetics and siRNA technology to target disease mechanisms in the nervous system. As of June 2025, EMP-014 remains in preclinical development and has not yet entered clinical trials or received regulatory approval[1][3][5].

Beyond the preview

Go deeper on EMP-014.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EMP-014.

Explore the full profile